One possible reason for the primary decrease in the mALBI score may be that the potent anti‐VEGF effect of bevacizumab causes tumor ischemia and inflammation; inflammation is likely to cause injury to the vascular endothelium and hypoalbuminemia as an expression of the inflammatory process.40, 41. The gene discussed is VEGFA; the disease is Hypoalbuminemia.